Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of MCL-1 expression in colorectal cancer.
Adams J, Stebbing J. Adams J, et al. Among authors: stebbing j. Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35308. Online ahead of print. Int J Cancer. 2024. PMID: 39740067 No abstract available.
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease.
Mato Prado M, Puik JR, Castellano L, López-Jiménez E, Liu DSK, Meijer LL, Le Large TYS, Rees E, Funel N, Sivakumar S, Pereira SP, Kazemier G, Zonderhuis BM, Erdmann JI, Swijnenburg RJ, Frilling A, Jiao LR, Stebbing J, Giovannetti E, Krell J, Frampton AE. Mato Prado M, et al. Among authors: stebbing j. Exp Hematol Oncol. 2023 Dec 1;12(1):101. doi: 10.1186/s40164-023-00458-3. Exp Hematol Oncol. 2023. PMID: 38041102 Free PMC article.
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators. Earl HM, et al. Lancet Oncol. 2015 Jun;16(6):656-66. doi: 10.1016/S1470-2045(15)70137-3. Epub 2015 May 11. Lancet Oncol. 2015. PMID: 25975632 Free article. Clinical Trial.
Kinome-Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma.
Vella V, Ditsiou A, Chalari A, Eravci M, Wooller SK, Gagliano T, Bani C, Kerschbamer E, Karakostas C, Xu B, Zhang Y, Pearl FMG, Lopez G, Peng L, Stebbing J, Klinakis A, Giamas G. Vella V, et al. Among authors: stebbing j. Adv Sci (Weinh). 2024 Apr;11(15):e2306027. doi: 10.1002/advs.202306027. Epub 2024 Feb 14. Adv Sci (Weinh). 2024. PMID: 38353396 Free PMC article.
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.
Glaviano A, Wander SA, Baird RD, Yap KC, Lam HY, Toi M, Carbone D, Geoerger B, Serra V, Jones RH, Ngeow J, Toska E, Stebbing J, Crasta K, Finn RS, Diana P, Vuina K, de Bruin RAM, Surana U, Bardia A, Kumar AP. Glaviano A, et al. Among authors: stebbing j. Drug Resist Updat. 2024 Sep;76:101103. doi: 10.1016/j.drup.2024.101103. Epub 2024 Jun 25. Drug Resist Updat. 2024. PMID: 38943828 Free article. Review.
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
Stebbing J, Baranau Y, Baryash V, Moiseyenko V, Boliukh D, Antone N, Manikhas A, Chornobai A, Park T, Baek EH, Lee J, Choi J, Kim N, Ahn K, Lee SJ, Kim S. Stebbing J, et al. BioDrugs. 2023 May;37(3):433-440. doi: 10.1007/s40259-023-00582-w. Epub 2023 Mar 7. BioDrugs. 2023. PMID: 36881323 Free PMC article. Clinical Trial.
Resveratrol and Female Fertility: A Systematic Review.
Bertoldo A, Pizzol D, Yon DK, Callegari M, Gobbo V, Cuccurese P, Butler L, Caminada S, Stebbing J, Richardson F, Gawronska J, Smith L. Bertoldo A, et al. Among authors: stebbing j. Int J Mol Sci. 2024 Nov 28;25(23):12792. doi: 10.3390/ijms252312792. Int J Mol Sci. 2024. PMID: 39684501 Free PMC article. Review.
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.
Chand D, Savitsky DA, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, Soh KT, Wu W, Wilkens MK, Udartseva O, Vincent S, Joshi B, Keith JG, Manrique M, Marques M, Tanne A, Levey DL, Han H, Ng S, Ridpath J, Huber O, Morin B, Galand C, Bourdelais S, Gombos RB, Ward R, Qin Y, Waight JD, Costa MR, Sebastian-Yague A, Rudqvist NP, Pupecka-Swider M, Venkatraman V, Slee A, Patel JM, Grossman JE, Wilson NS, Von Hoff DD, Stebbing J, Curiel TJ, Buell JS, O'Day SJ, Stein RB. Chand D, et al. Among authors: stebbing j. Cancer Discov. 2024 Dec 2;14(12):2407-2429. doi: 10.1158/2159-8290.CD-24-0190. Cancer Discov. 2024. PMID: 39083809 Free PMC article.
670 results